ClinicalTrials.gg

Migraine Disorders clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,659 studies for Migraine Disorders across more than 10 countries. 340 are recruiting or about to start. 1,428 of them are mainly about Migraine Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Migraine with Aura: 1,723 studies, 341 open.

ClinicalTrials.gov finds 1,830 studies for Migraine Disorders. How that becomes 1,658 here

This page counts the studies the registry files under Migraine Disorders, and those it files under no condition that list Migraine Disordersthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 1,830Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −64Filed under a narrower condition, counted on its own pageMigraine without Aura 42 · Migraine with Aura 22
  3. −79List Migraine Disorders as a condition, but the registry did not file them under itMost often written as “Chronic Migraine, Headache” (26), “Chronic Migraine” (22), and “Vestibular Migraine” (10). The registry filed them under other conditions only, most often Headache (38) and Fibromyalgia (8).
  4. −29Match it another way26 name it in the title and 3 in a keyword.
  5. 1,658The count on this page168 of them list Migraine Disorders in their own words; the registry filed them under no condition.

Status

Completed
970
Recruiting
217
Status unknown
134
Not yet recruiting
97
Terminated
96
Active, not recruiting
58

Phase

Phase 3
282
Phase 2
191
Phase 4
178
Phase 1
103
Early Phase 1
10

Where

United States
697
Italy
115
Denmark
98
Spain
97
Canada
94
Turkey
92

Who develops what

Add Migraine Disorders to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 11 companies, 13 with this as their studies’ main aim; 6 with a live phase 3 study; 9 primary completions in the next 12 months. Compare Pfizer, AbbVie and H. Lundbeck here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AcetaminophenRecent, limited
Evidence
  • NCT06245902 · Allodynic Therapeutics, Inc · Phase 2 · comparator · “Acetaminophen Alone” · registered Jan 2024
  • NCT05685225 · Allodynic Therapeutics, Inc · Phase 2 · comparator · “Stage 1: Acetaminophen” · registered Dec 2022
  • NCT03061734 · Allodynic Therapeutics, Inc · Phase 2 · comparator · “Acetaminophen Alone” · registered Feb 2017
  • NCT02582996 · Ache Laboratorios Farmaceuticos S.A. · Phase 3 · comparator · “Acetaminophen” · registered Mar 2015
  • NCT00758836 · Merck & Co., Inc · Phase 2 · background · “acetominophen” · registered Sep 2008
Johnson & Johnson29% of its industry studiesUS: off-patent, 109 generics marketed12 studies
TopiramateRecent, limited
Evidence
  • NCT05748483 · AbbVie · Phase 3 · comparator · “Topiramate” · registered Feb 2023
  • NCT03828539 · Novartis · Phase 4 · comparator · “Topiramate” · registered Feb 2019
Johnson & Johnson68% of its industry studiesUS: off-patent, 29 generics marketed11 study
NaltrexoneRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06245902 · Allodynic Therapeutics, Inc · Phase 2 · comparator · “Naltrexone Alone (regular dose)” · registered Jan 2024
  • NCT05685225 · Allodynic Therapeutics, Inc · Phase 2 · comparator · “Stage 1: Naltrexone” · registered Dec 2022
  • NCT03061734 · Allodynic Therapeutics, Inc · Phase 2 · comparator · “Naltrexone Alone (regular dose)” · registered Feb 2017
Orexigen Therapeutics, Inc26% of its industry studies12 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
rimegepantApproved: US 2020 · EU 2022☆ Track6 live phase-3 studies: NCT04743141, NCT04649242, NCT06616194Pfizer
elismetrep☆ Track3 live phase-3 studies: NCT07816367, NCT07674654, NCT07645924TriGemX Bio, Inc.
botulinum toxin type AApproved: US 1991 · EU 2019☆ Track2 live phase-3 studies: NCT07018700, NCT07018713Merz Pharma
eptinezumabApproved: US 2020 · EU 2022☆ Track3 live phase-3 studies: NCT04965675, NCT05897320, NCT05164172H. Lundbeck A/S
atogepantApproved: US 2021 · EU 2023☆ Track4 live phase-3 studies: NCT06810505, NCT05711394, NCT06806293AbbVie

The 5 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (9)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 29 Nov 2026 est.rimegepant · Pfizer · Phase 3 main aimNCT06641466 A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — primary endpoint: Mean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase · 723 enrolled
  • Feb 2027 est.elismetrep · TriGemX Bio, Inc. · Phase 3 main aimNCT07645924 A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — primary endpoint: Pain freedom at 2 hours post-dose · 1,800 enrolled
  • Mar 2027 est.botulinum toxin type A · Merz Pharma · Phase 3 main aimNCT07018700 A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — primary endpoint: Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A · 997 enrolled

6 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Migraine Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here CGRP receptor antagonists 19 open · Local anesthetics 6 open · Beta blockers 5 open · Calcium channel blockers 4 open · Serotonin receptor agonists 2 open

Coming up

117studies finish main data collection within a year14 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger. 44 (20%) take children under 18. 18 (8%) are for women only and 0 (0%) for men only; 37 (17%) take healthy volunteers.

Recruiting studies that take each age, of 217
AgeWomenMen
1031 (14%)30 (14%)
18182 (84%)165 (76%)
30190 (88%)172 (79%)
40190 (88%)172 (79%)
50181 (83%)171 (79%)
65156 (72%)149 (69%)
7594 (43%)88 (41%)
8573 (34%)67 (31%)

Across all 1,659 studies, recruiting or not: 67% stop at 75 or younger and 57% at 65; 15% take children; 7% are for women only and <1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Migraine Disorders studies take

Of 140 phase 3 interventional studies under Migraine Disorders, half reached primary completion within 19 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo2–19 · 53 studies4 mo2–12 · 39 studies—
Phase 215 mo11–30 · 73 studies12 mo7–20 · 43 studies—
Phase 2/318 mo10–23 · 12 studies——
Phase 319 mo12–40 · 140 studies18 mo11–31 · 114 studies—
Phase 427 mo17–37 · 77 studies27 mo17–33 · 28 studies29 mo18–51 · 49 studies
Interventional, no phase16 mo7–34 · 359 studies11 mo7–22 · 50 studies17 mo8–36 · 309 studies
Observational27 mo13–63 · 160 studies—27 mo13–72 · 132 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,659. Browse all 1,659 → or search them.